focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
When the market goes up we get left behind. When it goes down 2-3% we go down 10%...
Couldn't agree more Phil, the Woodford debacle caused havoc for many British healthcare SMEs, after a very long frustrating period for RENE investors it was the icing on the cake. At least that is all behind us, and for the first time in years I'm quite optomistic as many key milestones are in the pipeline. GLA.
Just found an Edison report from 2016: 'Our valuation has increased to £249m (vs £233m) or 7.9p per share (vs 7.4p per share)'. Considering the advances made and large licencing deal made, a market cap of a third of that now looks ridiculous.
Agree, but Edison had a price target of £330 12 years ago (£3.30 in today's money before the 1/100 reverse split). Interestingly their new target is £3.34 so I guess they haven't changed their position that much if you ignore the split and inflation!
Well we had another one today...
We really need to get off the AIM. A spread of 8.7%...
Mr Hunt commented:
"After twenty years at the Company, and with the business now in a much stronger financial position'.
Or in other words "After fleecing investors for twenty years I can't justify my existence anymore."
That's what I thought 14 years ago when I bought in at seven times this level.
Phil I dream about RENE being on the NASDAQ, the SP would be at least ten times as high. At this rate the company will end up getting bought for next to nothing and we'll all have wasted our time. The usual route for innovative British companies.
zahirmiahoutlook, I'm a long time holder of this company, 14 years to be precise and am not a deramper. I just get tired of childish idiots who post things like 'this is going to fly' etc which we've managed to avoid on this board until now. This is a really useful board for existing and potential investors, not barrowboys like you who can't even string a sentence together, let alone have anything valuable to say about the company. Oh and I will be blocking you, thanks.
zahirmiahoutlook can you stop posting rubbish on this board.
The share price has almost doubled in three weeks. I think something is afoot, possibly another licencing deal. Also funding secured so risk reduced.
I've never held any other share anywhere near as long. There have been so many false dawns and deadlines missed, but this is a very different company from 2007. Funding is pretty safe, a major licence agreement and all three product lines have huge potential. The management and communications are also far more professional. I think risk to the downside is low and any long term holders will be rewarded. Just hope it doesn't take another 14 years!
"I really think 10x+ is possible over 24-36 months from 70p entry."
That would take the SP to the level I got in at in 2007. This company owes me far more than that due to the opportunities I've missed elsewhere!
Hi can anyone translate the longest RNS ever into English? Do existing shareholders who don't take up the placing get the opportunity to buy 1 share for each 9 they hold at 1p each?
Thanks Grizzly and Chester. Presumably as their experience and knowledge increases incidences like this will become rarer and hopefully eliminated almost completely eventually. Agree that the last update was very exciting. Was a little despondent the SP barely reflected it.
Hi does anyone have any information on the two patients who had eyesight loss in the RP trials that I may have missed? I understand one had recovered partially but the other was more serious. Do we know what part of the procedure caused the damage and what mitigations are being put in place (if any exist) to reduce or prevent this reoccuring? Overall the results have been amazing, but this is an area I don't have a handle on regarding the statistical likelihood and extent of damage.
Thanks Chester, definitely a large private investor if he is doing this across multiple companies...
Have I missed something? Who is this Richard Griffiths chap?!
Thanks David and all the other people who have commented. Clive it's a good point about the loss of Woodford causing instability but having said that, I'm glad to see the back of him, it's one of the reasons our SP is so low. The wide spread may deter profit takers, but it also deters new investors getting in as they end up with a significant loss just by buying the shares.
13 years have passed since I got in and we are now at 20% of the SP. I completely agree that the science is unbelievable (as is the fact that this hasn't been recognised). There's a danger we'll end up getting bought out by a large pharma for peanuts and all this will have been a waste of time. Most holders would probably take double the current SP but that is actually nothing when you look at the licencing agreements and IP collected over the years.
Michael Hunt has impressed me more with his recent upbeat presentations, but they are still almost completely scientific, which isn't really what you expect from a CFO. I think the market needs some commercial confidence and clear deadlines. The clinical trials never seem to end or get passed Phase 2. Having said all that, this company has got some amazing potential which is why I have stuck it out so long.